The pharmacotherapeutic management of episodic and chronic migraine with gepants [PDF]
, 2023 The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment.
Csáti Anett +3 more
core +1 more source
Cephalalgia Reports, 2021 Objective: This randomized, partially-blinded, placebo-controlled study evaluated hemodynamic effects, pharmacokinetic interactions, and safety of concomitant administration of oral rimegepant and subcutaneous sumatriptan.
Robert Croop +9 more
doaj +1 more source
Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States. [PDF]
HeadacheAbstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Rosen N +6 more
europepmc +2 more sources
Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review [PDF]
, 2022 A significant proportion of patients exhibit sub-optimal response to the standard treatment of acute migraine such as triptans and NSAIDs. Even the conventional preventive therapies (e.g.
Ahsan, Marya, Mallick, Ayaz Khurram
core +2 more sources
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials [PDF]
, 2023 Migraine; PreventionMigranya; PrevencióMigraña; PrevenciónBackground Several novel treatments targeting the calcitonin gene-related peptide pathway have been developed for migraine.
Garcia Azorin, David +5 more
core +1 more source
A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. [PDF]
HeadacheAbstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
Kudrow D, Croop RS, Thiry A, Lipton RB.
europepmc +2 more sources
Mode and site of action of therapies targeting CGRP signaling [PDF]
, 2023 Calcitonin; Headache; MigraineCalcitonina; Dolor de cabeza; MigrañaCalcitonina; Mal de cap; MigranyaTargeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that ...
Braniste, Diana +5 more
core +4 more sources
Scientific Reports, 2023 Suppressing inflammation and abnormal subchondral bone turnover is essential for reducing osteoarthritis (OA) progression and pain relief. This study focused on calcitonin gene-related peptide (CGRP), which is involved in inflammation and bone metabolism,
Akinori Nekomoto +5 more
doaj +1 more source
Gepants, calcitonin gene-related peptide antagonists, for abortive treatment of migraine: current status [PDF]
, 2021 Migraine is a neurovascular disorder characterized by unilateral, recurrent, pulsating, throbbing, and moderate to severe headache. Triptans use is often limited by their poor efficacy, reports of poor responders, and contraindicated in patients with ...
Gaddam, Soni, Padi, Satyanarayana S. V.
core +2 more sources
New Gepants Against Acute Migraine A Systematic Review and Network Meta-Analysis
Amrita Journal of Medicine, 2021 Objectives: Recently two calcitonin gene-related peptide receptor antagonists (ubrogepant and rimegepant) were approved for the acute attack of migraine.
Dhyuti Gupta +2 more
doaj +1 more source